Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

25.89 +0.31 (+1.21%)

Official Closing Price Updated: 7:00 PM EST, Jan 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

"Animal Spirits" Return: Morgan Stanley Signals M&A Renaissance as Healthcare and Industrials Lead Shifting Landscape

January 15, 2026

As 2026 begins, the global mergers and acquisitions (M&A) market is witnessing a profound "renaissance," driven by a confluence of stabilizing interest rates, record levels of corporate cash, and a...

Via MarketMinute

These S&P500 stocks are the most active in today's session ↗

January 15, 2026

Via Chartmill

The Execution Engine: How Merck is Dominating the 2026 Pharma Landscape

January 15, 2026

As of January 15, 2026, Merck & Co. (NYSE: MRK) has emerged as the standout performer in the pharmaceutical sector, defying the gravity of looming patent expirations with a series of strategic...

Via MarketMinute

Topics Economy Intellectual Property

Most active S&P500 stocks in Tuesday's session ↗

January 13, 2026

Via Chartmill

Healthcare Titan Ascendant: Johnson & Johnson Hits All-Time Highs as It Navigates a New Political and Clinical Era

January 15, 2026

As of January 15, 2026, Johnson & Johnson (NYSE: JNJ) has emerged as the undisputed pacesetter of the healthcare sector, with its stock price surging to an all-time high of $218.53. This milestone...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Earnings

3 Volatile Stocks We Keep Off Our Radar

January 14, 2026

A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared.

Via StockStory

Curious about the most active S&P500 stocks in today's session? ↗

January 14, 2026

Via Chartmill

The Great Tariff-Inflation Tug-of-War: Why the Fed’s 2% Target Remains Elusive in 2026

January 14, 2026

As the United States enters the first quarter of 2026, the global economy is grappling with a radical shift in trade dynamics that has upended decades of globalization. The aggressive...

Via MarketMinute

Topics Economy Supply Chain World Trade

Viatris Inc. (NASDAQ: VTRS): Navigating the Pivot from Integration to Innovation

January 14, 2026

Date: January 14, 2026 Viatris Inc. (NASDAQ: VTRS) stands at a critical crossroads in early 2026. After years of functioning as a complex, debt-laden conglomerate formed from the massive merger of...

Via Finterra

Topics Earnings Economy Intellectual Property

Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot

January 14, 2026

Once the poster child for the biotechnology sector’s rapid response to the global pandemic, Moderna, Inc. (Nasdaq: MRNA) finds itself at a critical crossroads in early 2026. After a tumultuous period...

Via Finterra

Topics Initial Public Offering Intellectual Property

Is It Time to Dump Your Shares of Eli Lilly? ↗

January 14, 2026

What happens with Eli Lilly's GLP-1 shot now that Novo Nordisk has come out with a GLP-1 pill?

Via The Motley Fool

Topics Intellectual Property

The Great Recalibration: Why 2026 Could Be Healthcare’s Year to Rebound

January 13, 2026

For the past two years, the U.S. healthcare sector has been the forgotten stepchild of the equity markets. As the S&P 500 (SPX) surged on the back of an artificial intelligence gold rush and a...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance

January 13, 2026

Date: January 13, 2026 Introduction Amgen Inc. (NASDAQ: AMGN) finds itself at a historic crossroads. Long regarded as the "blue-chip" anchor of the biotechnology sector, the Thousand Oaks-based giant...

Via PredictStreet

Topics Economy Intellectual Property

The Evolution of a Giant: A Deep Dive into the ‘New’ Johnson & Johnson (JNJ) in 2026

January 13, 2026

As of January 13, 2026, Johnson & Johnson (NYSE: JNJ) stands at a pivotal juncture in its nearly 140-year history. Once a sprawling conglomerate synonymous with baby shampoo and Band-Aids, the "New...

Via PredictStreet

Topics Artificial Intelligence Bankruptcy Economy

3 Value Stocks That Fall Short

January 12, 2026

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

Why Tempus AI Stock Rose Today ↗

January 12, 2026

The data provider's artificial intelligence-driven solutions are accelerating drug discovery.

Via The Motley Fool

Topics Artificial Intelligence

The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape

January 12, 2026

As the 44th Annual J.P. Morgan Healthcare Conference concludes in early January 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a critical crossroads. Once the darling of the pandemic era, the...

Via MarketMinute

Topics Economy Intellectual Property World Trade

Pfizer CEO Eyes Big Push Towards Obesity Drug Development In 2026 After $10B Metsera Acquisition ↗

January 12, 2026

Pfizer’s CEO Albert Bourla is looking to initiate about 10 late-stage trials of the company’s new obesity drugs.

Via Stocktwits

Stay informed about the most active stocks in the S&P500 index on Monday's session. ↗

January 12, 2026

Via Chartmill

Pfizer Cancer Combo Drug Shows Strong Tumor Shrinkage in Colorectal Cancer Trial ↗

January 12, 2026

Pfizer shared new trial data showing its cancer drug combo helped shrink tumors more often than standard treatment in advanced colorectal cancer patients at a major oncology meeting.

Via Benzinga

This ETF Is Proof That the Healthcare Rebound Is Real ↗

January 11, 2026

Via MarketBeat

Topics ETFs

This Healthcare Stock Could Be One of the Best Companies to Own in 2026 ↗

January 11, 2026

It has strong momentum thanks to its current portfolio and several catalysts on the horizon.

Via The Motley Fool

Unusual Options Activity in Pfizer: 2 Strategies Traders Are Jumping On

January 09, 2026

There were 1,399 unusually active options in Thursday’s trading. Pfizer’s March 20 $29 put had the highest Vol/OI ratio at 210.16. In the money by 12.8%, it sets up for a couple of different trading...

Via Barchart.com

Cashing In at the Peak: Olema Pharmaceuticals Insiders Sell $8 Million in Stock After 300% Surge

January 09, 2026

Olema Pharmaceuticals (NASDAQ:OLMA) has become the latest focal point of biotech volatility and executive opportunism. Following a staggering 300% surge in its share price over the past year—fueled by...

Via MarketMinute

The Great Pricing Pivot: Novo Nordisk Launches Wegovy Pill in Bid to Reclaim US Market Dominance

January 09, 2026

As the first full week of 2026 unfolds, the pharmaceutical landscape is witnessing a seismic shift led by the Danish healthcare giant Novo Nordisk (NYSE: NVO). On January 5, 2026, the company...

Via MarketMinute

Topics Economy

The Trillion-Dollar Pharmacist: A 2026 Deep Dive into Eli Lilly (LLY)

January 09, 2026

As of January 9, 2026, Eli Lilly and Company (NYSE:LLY) has transitioned from a stalwart of the American pharmaceutical industry to a global financial phenomenon. Having recently crossed the historic...

Via PredictStreet

Topics Earnings Economy Intellectual Property

BioNTech Finalizes CureVac Acquisition: A Strategic Consolidation Met with Market Skepticism

January 09, 2026

In a move that signals the end of an era for independent mRNA pioneers, BioNTech SE (Nasdaq: BNTX) has officially completed its acquisition of longtime rival CureVac N.V. (Nasdaq: CVAC). The...

Via MarketMinute

Topics Intellectual Property

Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026 ↗

January 09, 2026

It could be another tough year for the once-soaring drugmaker.

Via The Motley Fool

Topics Intellectual Property

Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics

January 09, 2026

Today’s Date: January 9, 2026 Introduction As we enter the first weeks of 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a defining crossroads. Once the poster child for the biotech boom of the...

Via PredictStreet

Topics Initial Public Offering Intellectual Property

J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗

January 08, 2026

Via Stocktwits

Topics Government

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.